Exabis Library
Welcome to the e-CCO Library!
P530: Azathioprine in the maintenance of steroid-free remission in inflammatory bowel disease patients: efficacy and safety in five years of follow-up
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P530: Proactive therapeutic drug monitoring of anti-TNF agents is associated with higher mucosal healing rates in Crohn's disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P530: Psychosexual dysfunction in Greek patients with inflammatory bowel disease in remission
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P530: The Burden on Cohabitants of Patients with Inflammatory Bowel Disease: A Cross-Sectional Study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P530: Ultra-proactive therapeutic drug monitoring incorporating infliximab point-of-care testing with ad hoc dose adjustment reduces C-reactive protein levels in patients with IBD during infliximab maintenance treatment
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P530: Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease - a systematic review with meta-analysis
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P531 A retrospective audit of the inflammatory bowel disease specialist nurse-led telephone advice service
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P531: A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P531: Discontinuation of corticosteroids among Crohn's disease patients treated with vedolizumab in the United States
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P531: Efficacy of tofacitinib maintenance therapy for ulcerative colitis in remitting patients vs. patients with clinical response after 8 weeks of induction treatment
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P531: SARS-CoV-2 infection in Elderly patients with Inflammatory Bowel Disease with or without immunosuppressants during the first year of the pandemic. An observational, descriptive, cohort study.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P531: Stringent screening strategy significantly reduces reactivation rate of Tuberculosis in Patients with Inflammatory Bowel Disease on anti-TNF therapy in a TB endemic region
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P531: Tuberculin skin test conversion rate in inflammatory bowel disease patients receiving anti-TNFα agents
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P532 Measuring endoscopic activity in patients treated with vedolizumab for ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P532: 1-Year Clinical Outcome of Subcutaneous Infliximab compared with Intravenous Infliximab in Patients with Inflammatory Bowel Disease During Maintenance Therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P532: Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients – one-year clinical follow-up
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P532: Delay of maintenance infliximab increases the risk of relapse in Crohn’s disease during the COVID-19 pandemic
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P532: Efficacy of combination therapy with cyclosporin and vedolizumab in inflammatory bowel diseases refractory to anti-TNF agents
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P532: Proactive therapeutic drug monitoring improves clinical outcomes in patients with inadequate post-induction infliximab trough levels
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P532: Safety and efficacy of endoscopic dilation of small bowel Crohn’s disease strictures by balloon-assisted enteroscopy: pooled analysis of individual data from 210 patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM